Title |
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)
|
---|---|
Published in |
Journal of Thoracic Oncology, October 2012
|
DOI | 10.1097/jto.0b013e318265b2b5 |
Pubmed ID | |
Authors |
Jacques Cadranel, Audrey Mauguen, Michele Faller, Gérard Zalcman, Marie-Pierre Buisine, Virginie Westeel, Elisabeth Longchampt, Marie Wislez, Bruno Coudert, Catherine Daniel, Bruno Chetaille, Stephane Michiels, Helene Blons, Jerome Solassol, Florence De Fraipont, Pascal Foucher, Thierry Urban, Ludovic Lacroix, Virginie Poulot, Elisabeth Quoix, Martine Antoine, Guillaume Danton, Franck Morin, Christos Chouaid, Jean-Pierre Pignon, on behalf of the ERMETIC collaborative group and the Intergroupe Francophone de Cancerologie Thoracique |
Abstract |
Epidermal growth factor and v-Ki-ras2 Kirsten ras sarcoma (KRAS) mutation status, although associated with EGFR- tyrosine kinase inhibitor (TKI) efficacy, has not been used in clinical practice until recently. The prospective Evaluation of the EGFR Mutation status for the administration of EGFR-TKIs in non small cell lung Carcinoma (ERMETIC) study aimed to implement these biomarkers in France. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 1% |
France | 1 | 1% |
Ireland | 1 | 1% |
Unknown | 74 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 18% |
Student > Ph. D. Student | 11 | 14% |
Student > Master | 10 | 13% |
Other | 9 | 12% |
Student > Bachelor | 6 | 8% |
Other | 16 | 21% |
Unknown | 11 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 42 | 55% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Nursing and Health Professions | 3 | 4% |
Agricultural and Biological Sciences | 3 | 4% |
Mathematics | 3 | 4% |
Other | 10 | 13% |
Unknown | 12 | 16% |